Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

H. Yoshioka, M. Shimokawa, T. Seto, S. Morita, Y. Yatabe, I. Okamoto, J. Tsurutani, M. Satouchi, T. Hirashima, S. Atagi, K. Shibata, H. Saito, S. Toyooka, N. Yamamoto, K. Nakagawa, T. Mitsudomi

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Fingerprint Dive into the research topics of 'Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences